Basic Information
| LncRNA/CircRNA Name | HOXA11-AS |
| Synonyms | HOXA11-AS, HOXA-AS5, HOXA11-AS1, HOXA11AS, HOXA11S, NCRNA00076 |
| Region | GRCh38_7:27184518-27189293 |
| Ensemble | ENSG00000240990 |
| Refseq | NR_002795 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR etc. |
| Sample | breast tissues, cell lines (MDA-MB-231, MDA-MB-436, MCF7, T47D) |
| Expression Pattern | up-regulated |
| Function Description | The data revealed that the relative transcript level of HOXA11-AS was upregulated in vivo and in vitro in models of breast cancer. Knockdown of HOXA11-AS in MDA-MB-231 and MDA-MB-436 breast cancer cell lines inhibited the formation of cell colonies and arrested the cell cycle at the G0/G1 phase. Depletion of HOXA11-AS using two specific short interfering (si)RNAs against HOXA11-AS (siHOXA11-AS-1 and siHOXA11-AS-2) additionally suppressed the cell proliferative rate. Furthermore, transwell assays and wound-healing analysis revealed that siRNA transfection inhibited cell migration and invasion by ~50% in the two cell lines. The results of the present study demonstrated the oncogenic role of HOXA11-AS in breast cancer, providing novel clues for the future clinical diagnosis and treatment of early stage breast cancer patients. |
| Pubmed ID | 28791375 |
| Year | 2017 |
| Title | Long non-coding RNA HOXA11-AS promotes cell proliferation and metastasis in human breast cancer |
External Links
| Links for HOXA11-AS | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |